* Outset Medical Inc OM.OQ OM.O is expected to show a rise
in quarterly revenue when it reports results on November 3.
* The San Jose, California-based company is expected to report
a 82.6% increase in revenue to $25.123 million from $13.76
million a year ago, according to the mean estimate from 6
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Outset Medical Inc is
for a loss of 73 cents per share. For the same quarter last
year, the company reported a loss of $3.31 per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for Outset Medical
Inc is $63.5, about 7.8% above its last closing price
of $58.53.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Jun. 302021 -0.69 -0.70 -0.66 Beat 5.4
Mar. 312021 -0.80 -0.81 -0.70 Beat 13.7
Dec. 312020 -0.66 -0.66 -0.75 Missed -13
Sep. 302020 -3.10 -3.10 -3.31 Missed -6.7
This summary was machine generated November 2 at 02:07 GMT. All
figures in US dollars unless otherwise stated